Skip to main content
. Author manuscript; available in PMC: 2015 Jul 13.
Published in final edited form as: Epilepsia. 2011 Mar 22;52(4):810–815. doi: 10.1111/j.1528-1167.2011.03025.x

Table 2.

Switchback rates

Patient characteristic Switchback rate (%)
Total 42.9
Gender
 Male 41.2
 Female 44.3
Monotherapy versus polytherapy
 Monotherapy 39.1
 Polytherapy 44.9
Seizure type
 Idiopathic 33.3
 Symptomatic 52.3
 Cryptogenic 35.4
Increased adverse effects on generic LEV
 No increased adverse effects on generic 40.9
 Increased adverse effects on generic 100
Increased adverse effects on brand LEV
 No increased adverse effects on brand 41.2
 Increased adverse effects on brand 100
Increased seizures on generic LEV (rel to brand)
 No increased seizures on generic (decreased or no change) 28.9
 Increased seizures on generic 100